Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

Expedited approval programs at the Food and Drug Administration.

Begg CB, Ellenberg SS.

Clin Trials. 2018 Jun;15(3):217-218. doi: 10.1177/1740774518770653. No abstract available.

PMID:
29871506
2.

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Thomas NE, Edmiston SN, Orlow I, Kanetsky PA, Luo L, Gibbs DC, Parrish EA, Hao H, Busam KJ, Armstrong BK, Kricker A, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962-6. doi: 10.1016/j.jid.2018.04.025. [Epub ahead of print]

3.

RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY".

Begg CB, Seshan VE, Zabor EC.

Am J Epidemiol. 2018 May 1;187(5):1129-1130. doi: 10.1093/aje/kwy032. No abstract available.

PMID:
29528373
4.

Zero tolerance for acronyms.

Begg CB.

Clin Trials. 2017 Dec;14(6):561-562. doi: 10.1177/1740774517740570. No abstract available.

PMID:
29198178
5.

The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival.

Orlow I, Shi Y, Kanetsky PA, Thomas NE, Luo L, Corrales-Guerrero S, Cust AE, Sacchetto L, Zanetti R, Rosso S, Armstrong BK, Dwyer T, Venn A, Gallagher RP, Gruber SB, Marrett LD, Anton-Culver H, Busam K, Begg CB, Berwick M; GEM Study Group.

Pigment Cell Melanoma Res. 2018 Mar;31(2):287-296. doi: 10.1111/pcmr.12653. Epub 2017 Nov 5.

PMID:
28990310
6.

Contralateral breast cancers: Independent cancers or metastases?

Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS.

Int J Cancer. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28.

PMID:
28921573
7.

Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Thomas NE, Edmiston SN, Kanetsky PA, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gruber SB, Luo L, Orlow I, Reiner AS, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Parrish EA, Hao H, Gibbs DC, Frank JS, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2017 Dec;137(12):2588-2598. doi: 10.1016/j.jid.2017.07.832. Epub 2017 Aug 24.

PMID:
28842324
8.

A comparison of statistical methods for the study of etiologic heterogeneity.

Zabor EC, Begg CB.

Stat Med. 2017 Nov 10;36(25):4050-4060. doi: 10.1002/sim.7405. Epub 2017 Jul 26.

PMID:
28748599
9.

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Vernali S, Waxweiler WT, Dillon PM, Kanetsky PA, Orlow I, Luo L, Busam KJ, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

JAMA Dermatol. 2017 Oct 1;153(10):1026-1031. doi: 10.1001/jamadermatol.2017.2444.

PMID:
28746718
10.

Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.

Gibbs DC, Ward SV, Orlow I, Cadby G, Kanetsky PA, Luo L, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Br J Dermatol. 2017 Nov;177(5):e180-e182. doi: 10.1111/bjd.15784. Epub 2017 Oct 6. No abstract available.

PMID:
28667740
11.

Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma.

Mauguen A, Zabor EC, Thomas NE, Berwick M, Seshan VE, Begg CB.

J Am Stat Assoc. 2017;112(517):54-63. doi: 10.1080/01621459.2016.1191499. Epub 2017 May 3.

12.

Estimating the probability of clonal relatedness of pairs of tumors in cancer patients.

Mauguen A, Seshan VE, Ostrovnaya I, Begg CB.

Biometrics. 2018 Mar;74(1):321-330. doi: 10.1111/biom.12710. Epub 2017 May 8.

13.

No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study.

Schwitzer E, Orlow I, Zabor EC, Begg CB, Berwick M, Thomas NE, Kanetsky PA, Jones LW; GEM Study Group.

Pigment Cell Melanoma Res. 2017 Jul;30(4):424-427. doi: 10.1111/pcmr.12594. Epub 2017 Jun 8. No abstract available.

14.

Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.

Begg CB, Rice MS, Zabor EC, Tworoger SS.

Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23.

15.

An efficient basket trial design.

Cunanan KM, Iasonos A, Shen R, Begg CB, Gönen M.

Stat Med. 2017 May 10;36(10):1568-1579. doi: 10.1002/sim.7227. Epub 2017 Jan 18.

16.

Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Campbell PT, Rebbeck TR, Nishihara R, Beck AH, Begg CB, Bogdanov AA, Cao Y, Coleman HG, Freeman GJ, Heng YJ, Huttenhower C, Irizarry RA, Kip NS, Michor F, Nevo D, Peters U, Phipps AI, Poole EM, Qian ZR, Quackenbush J, Robins H, Rogan PK, Slattery ML, Smith-Warner SA, Song M, VanderWeele TJ, Xia D, Zabor EC, Zhang X, Wang M, Ogino S.

Cancer Causes Control. 2017 Feb;28(2):167-176. doi: 10.1007/s10552-016-0845-z. Epub 2017 Jan 17. Review.

17.

Editorial.

Begg CB.

Clin Trials. 2016 Dec;13(6):573. No abstract available.

PMID:
27903946
18.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A.

J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. No abstract available.

19.

Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study.

White KA, Luo L, Thompson TA, Torres S, Hu CA, Thomas NE, Lilyquist J, Anton-Culver H, Gruber SB, From L, Busam KJ, Orlow I, Kanetsky PA, Marrett LD, Gallagher RP, Sacchetto L, Rosso S, Dwyer T, Cust AE, Begg CB, Berwick M; GEM Study Group.

Cancer Med. 2016 Nov;5(11):3336-3345. doi: 10.1002/cam4.929. Epub 2016 Oct 17.

20.

Cautionary Note on Using Cross-Validation for Molecular Classification.

Qin LX, Huang HC, Begg CB.

J Clin Oncol. 2016 Nov 10;34(32):3931-3938. doi: 10.1200/JCO.2016.68.1031.

21.

Editorial.

Begg CB.

Clin Trials. 2016 Aug;13(4):371. doi: 10.1177/1740774516652020. No abstract available.

PMID:
27402084
22.

Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, Schizas M, De Brot M, Andrade VP, Mauguen A, Seshan VE, King TA.

Breast Cancer Res. 2016 Jun 23;18(1):66. doi: 10.1186/s13058-016-0727-z.

23.

Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Taylor NJ, Thomas NE, Anton-Culver H, Armstrong BK, Begg CB, Busam KJ, Cust AE, Dwyer T, From L, Gallagher RP, Gruber SB, Nishri DE, Orlow I, Rosso S, Venn AJ, Zanetti R, Berwick M, Kanetsky PA; GEM Study Group.

Int J Cancer. 2016 Sep 15;139(6):1217-22. doi: 10.1002/ijc.30157. Epub 2016 May 30.

24.

Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity.

Mauguen A, Begg CB.

Epidemiology. 2016 Jul;27(4):531-7. doi: 10.1097/EDE.0000000000000499.

25.

Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways.

Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

J Natl Cancer Inst. 2016 Feb 8;108(7). pii: djw004. doi: 10.1093/jnci/djw004. Print 2016 Jul.

26.

USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS.

Ostrovnaya I, Seshan VE, Begg CB.

Ann Appl Stat. 2015 Sep;9(3):1533-1548. Epub 2015 Nov 2.

27.

Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study.

Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, Paine S, Armstrong BK, Kricker A, Marrett LD, Rosso S, Zanetti R, Gruber SB, Anton-Culver H, Gallagher RP, Dwyer T, Busam K, Begg CB, Berwick M; GEM Study Group.

Carcinogenesis. 2016 Jan;37(1):30-8. doi: 10.1093/carcin/bgv157. Epub 2015 Oct 31.

28.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

29.

Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer.

Begg CB, Orlow I, Zabor EC, Arora A, Sharma A, Seshan VE, Bernstein JL.

Cancer Med. 2015 Sep;4(9):1432-9. doi: 10.1002/cam4.456. Epub 2015 May 13.

30.

Proceedings of the second international molecular pathological epidemiology (MPE) meeting.

Ogino S, Campbell PT, Nishihara R, Phipps AI, Beck AH, Sherman ME, Chan AT, Troester MA, Bass AJ, Fitzgerald KC, Irizarry RA, Kelsey KT, Nan H, Peters U, Poole EM, Qian ZR, Tamimi RM, Tchetgen Tchetgen EJ, Tworoger SS, Zhang X, Giovannucci EL, van den Brandt PA, Rosner BA, Wang M, Chatterjee N, Begg CB.

Cancer Causes Control. 2015 Jul;26(7):959-72. doi: 10.1007/s10552-015-0596-2. Epub 2015 May 9.

31.

Inherited genetic variants associated with occurrence of multiple primary melanoma.

Gibbs DC, Orlow I, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):992-7. doi: 10.1158/1055-9965.EPI-14-1426. Epub 2015 Apr 2.

32.

Inherited variation at MC1R and histological characteristics of primary melanoma.

Taylor NJ, Busam KJ, From L, Groben PA, Anton-Culver H, Cust AE, Begg CB, Dwyer T, Gallagher RP, Gruber SB, Orlow I, Rosso S, Thomas NE, Zanetti R, Rebbeck TR, Berwick M, Kanetsky PA.

PLoS One. 2015 Mar 19;10(3):e0119920. doi: 10.1371/journal.pone.0119920. eCollection 2015.

33.

Ethical concerns about adaptive randomization.

Begg CB.

Clin Trials. 2015 Apr;12(2):101. doi: 10.1177/1740774515569613. No abstract available.

PMID:
25755226
34.

Genomic investigation of etiologic heterogeneity: methodologic challenges.

Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ.

BMC Med Res Methodol. 2014 Dec 22;14:138. doi: 10.1186/1471-2288-14-138.

35.

Inherited variation at MC1R and ASIP and association with melanoma-specific survival.

Taylor NJ, Reiner AS, Begg CB, Cust AE, Busam KJ, Anton-Culver H, Dwyer T, From L, Gallagher RP, Gruber SB, Rosso S, White KA, Zanetti R, Orlow I, Thomas NE, Rebbeck TR, Berwick M, Kanetsky PA; GEM Study Group.

Int J Cancer. 2015 Jun 1;136(11):2659-67. doi: 10.1002/ijc.29317. Epub 2014 Nov 26.

36.

"Right to Try" laws.

Begg CB, Kim K, Neaton JD.

Clin Trials. 2014 Oct;11(5):519-20. doi: 10.1177/1740774514546574. No abstract available.

PMID:
25190026
37.

Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Thomas NE, Kricker A, Waxweiler WT, Dillon PM, Busman KJ, From L, Groben PA, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Orlow I, Paine S, Ollila DW, Reiner AS, Luo L, Hao H, Frank JS, Begg CB, Berwick M; Genes, Environment, and Melanoma (GEM) Study Group.

JAMA Dermatol. 2014 Dec;150(12):1306-314.

38.

Sun exposure and melanoma survival: a GEM study.

Berwick M, Reiner AS, Paine S, Armstrong BK, Kricker A, Goumas C, Cust AE, Thomas NE, Groben PA, From L, Busam K, Orlow I, Marrett LD, Gallagher RP, Gruber SB, Anton-Culver H, Rosso S, Zanetti R, Kanetsky PA, Dwyer T, Venn A, Lee-Taylor J, Begg CB; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2145-52. doi: 10.1158/1055-9965.EPI-14-0431. Epub 2014 Jul 28.

39.

Blocking and randomization to improve molecular biomarker discovery.

Qin LX, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, Satagopan JM, Begg CB, Levine DA.

Clin Cancer Res. 2014 Jul 1;20(13):3371-8. doi: 10.1158/1078-0432.CCR-13-3155. Epub 2014 May 1.

40.

Breast cancer after chest radiation therapy for childhood cancer.

Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC.

J Clin Oncol. 2014 Jul 20;32(21):2217-23. doi: 10.1200/JCO.2013.54.4601. Epub 2014 Apr 21.

41.

Editorial transition.

Begg CB.

Clin Trials. 2014 Feb;11(1):5-6. doi: 10.1177/1740774513515551. No abstract available.

PMID:
24492146
42.

MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.

Berwick M, MacArthur J, Orlow I, Kanetsky P, Begg CB, Luo L, Reiner A, Sharma A, Armstrong BK, Kricker A, Cust AE, Marrett LD, Gruber SB, Anton-Culver H, Zanetti R, Rosso S, Gallagher RP, Dwyer T, Venn A, Busam K, From L, White K, Thomas NE; GEM Study Group.

Pigment Cell Melanoma Res. 2014 May;27(3):485-8. doi: 10.1111/pcmr.12215. Epub 2014 Jan 30.

43.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H, Begg CB, Berwick M.

J Clin Oncol. 2013 Nov 20;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. Epub 2013 Oct 14.

44.

Justifying the choice of endpoints for clinical trials.

Begg CB.

J Natl Cancer Inst. 2013 Nov 6;105(21):1594-5. doi: 10.1093/jnci/djt289. Epub 2013 Oct 9. No abstract available.

PMID:
24108810
45.

Testing the incremental predictive accuracy of new markers.

Begg CB, Gonen M, Seshan VE.

Clin Trials. 2013 Oct;10(5):690-2. doi: 10.1177/1740774513496490. Epub 2013 Jul 23.

46.

A conceptual and methodological framework for investigating etiologic heterogeneity.

Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE.

Stat Med. 2013 Dec 20;32(29):5039-52. doi: 10.1002/sim.5902. Epub 2013 Jul 16.

47.

An assessment of estimation methods for generalized linear mixed models with binary outcomes.

Capanu M, Gönen M, Begg CB.

Stat Med. 2013 Nov 20;32(26):4550-66. doi: 10.1002/sim.5866. Epub 2013 Jul 9.

48.

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative Group.

Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.

49.

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.

Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC, Haile RW, Thomas DC, Begg CB, Bernstein JL.

J Clin Oncol. 2013 Feb 1;31(4):433-9. doi: 10.1200/JCO.2012.43.2013. Epub 2012 Dec 26.

50.

Comparing ROC curves derived from regression models.

Seshan VE, Gönen M, Begg CB.

Stat Med. 2013 Apr 30;32(9):1483-93. doi: 10.1002/sim.5648. Epub 2012 Oct 3.

Supplemental Content

Support Center